Level Biotechnology (3118) — Cash Flow Quality Index
Level Biotechnology (3118) has a Cash Flow Quality Index of 0.44x as of September 2025. Operating cash flow of NT$11.81 Million is below net income of NT$26.84 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Level Biotechnology (3118) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Level Biotechnology Cash Flow Quality Index (2017–2024)
Historical Cash Flow Quality Index for Level Biotechnology across 8 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 3118 cash flow conversion.
Annual Cash Flow Quality Index for Level Biotechnology (2017–2024)
Year-by-year earnings quality comparison for Level Biotechnology.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.99x | NT$64.10 Million | NT$64.81 Million | ▲ +10.8% |
| 2023 | 0.89x | NT$70.21 Million | NT$78.65 Million | ▲ +0.4% |
| 2022 | 0.89x | NT$65.07 Million | NT$73.16 Million | ▼ -51.6% |
| 2021 | 1.84x | NT$155.95 Million | NT$84.89 Million | ▲ +60.1% |
| 2020 | 1.15x | NT$83.23 Million | NT$72.54 Million | ▼ -50.1% |
| 2019 | 2.30x | NT$109.02 Million | NT$47.40 Million | ▲ +234.3% |
| 2018 | 0.69x | NT$26.77 Million | NT$38.91 Million | ▼ -34.1% |
| 2017 | 1.04x | NT$71.29 Million | NT$68.31 Million | — |